Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Stoke Therapeutics, Inc. (STOK)
USD29.24
-0.22 (-0.76%)
US NASDAQ Healthcare Biotechnology
Address
45 Wiggins Avenue 1730
Bedford, MA, US
Bedford, MA, US
CEO
Ian F. Smith
Website
stoketherapeutics.com
IPO
2019-06-19
CIK 1623526 ISIN US86150R1077
Description
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD29.24
-0.22 (-0.76%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
699.4K
Beta
1.18
Float Shares
48.93M
Free Float %
82.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.76% | -1.00% | -4.92% | +2.35% | +29.88% | +2.84% | +237.89% | +185.31% | -8.85% | +27.65% | +27.65% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (15 ratings, all time)
Buy
Price Targets & DCF
Current price
29.24
Low
35.00
+19.7%
Consensus
43.86
+50.0%
Median
40.00
+36.8%
High
60.00
+105.2%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 11 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
40.00
+36.8%
|
| Last Year | 10 |
39.80
+36.1%
|
| All Time | 17 |
35.12
+20.1%
|
Quality scores
Altman Z-Score
23.07
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+404.5% ★ Q1'26: -96.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+92.7% ★ Q1'26: -141.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1.7% Q1'26: -978.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-11.2% Q1'26: -857.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-30.4% Q1'26: -390.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+9.7% Q1'26: +6.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: -0.02× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 9 EPS Ana. |
Dec 2027 7 Rev. Ana. 7 EPS Ana. |
Dec 2028 9 Rev. Ana. 8 EPS Ana. |
Dec 2029 4 Rev. Ana. 6 EPS Ana. |
Dec 2030 4 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
12.41M
est: 11.70M (+6.0%)
|
8.78M
est: 15.16M (-42.1%)
|
36.56M
est: 17.92M (+104.0%)
|
184.42M
est: 188.80M (-2.3%)
|
26.32M
18.46M – 35.67M
-86.1% YoY
|
49.23M
35.85M – 59.15M
+87.0% YoY
|
122.48M
120.65M – 124.31M
+148.8% YoY
|
340.75M
163.80M – 548.82M
+178.2% YoY
|
561.65M
269.99M – 904.61M
+64.8% YoY
|
| EBITDA |
-102.81M
est: -2.34M (-4,294.5%)
|
-112.30M
est: -6.37M (-1,662.4%)
|
-99.20M
est: -7.53M (-1,216.5%)
|
-18.82M
est: -79.37M (+76.3%)
|
-11.07M
-15.00M – -7.76M
+86.1% YoY
|
-20.70M
-24.87M – -15.07M
-87.0% YoY
|
-51.49M
-52.26M – -50.72M
-148.8% YoY
|
-143.25M
-230.73M – -68.86M
-178.2% YoY
|
-236.12M
-380.31M – -113.50M
-64.8% YoY
|
| EBIT |
-104.36M
est: -2.34M (-4,360.6%)
|
-114.77M
est: -6.40M (-1,693.0%)
|
-101.37M
est: -7.57M (-1,239.3%)
|
-20.59M
est: -79.74M (+74.2%)
|
-11.12M
-15.07M – -7.80M
+86.1% YoY
|
-20.79M
-24.98M – -15.14M
-87.0% YoY
|
-51.73M
-52.50M – -50.96M
-148.8% YoY
|
-143.91M
-231.78M – -69.18M
-178.2% YoY
|
-237.20M
-382.05M – -114.02M
-64.8% YoY
|
| Net Income |
-101.07M
est: -144.83M (+30.2%)
|
-104.70M
est: -103.57M (-1.1%)
|
-88.98M
est: -120.98M (+26.4%)
|
-6.89M
est: 12.70M (-154.2%)
|
-214.92M
-218.62M – -174.56M
-1,792.9% YoY
|
-211.48M
-225.48M – -129.02M
+1.6% YoY
|
-147.64M
-202.28M – -40.46M
+30.2% YoY
|
1.11M
360.8K – 1.99M
+100.8% YoY
|
86.83M
28.21M – 155.76M
+7,720.0% YoY
|
| SGA |
38.92M
est: 26.15M (+48.8%)
|
41.32M
est: 31.96M (+29.3%)
|
48.79M
est: 37.79M (+29.1%)
|
67.09M
est: 398.10M (-83.1%)
|
55.50M
38.92M – 75.22M
-86.1% YoY
|
103.80M
75.58M – 124.71M
+87.0% YoY
|
258.26M
254.40M – 262.11M
+148.8% YoY
|
718.49M
345.37M – 1.16B
+178.2% YoY
|
1.18B
569.28M – 1.91B
+64.8% YoY
|
| EPS |
-2.60
est: -2.66 (+2.3%)
|
-2.38
est: -2.16 (-10.2%)
|
-1.65
est: -2.02 (+18.2%)
|
-0.12
est: 0.12 (-198.0%)
|
-3.25
-3.69 – -2.95
-2,755.4% YoY
|
-3.07
-3.81 – -2.18
+5.7% YoY
|
-2.14
-3.42 – -0.68
+30.3% YoY
|
0.02
0.01 – 0.03
+100.9% YoY
|
1.47
0.48 – 2.63
+7,720.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-182.94M
OE per share TTM
-3.01
Owner's Yield
-8.85%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
22.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
35
Total invested
57.53M
Insider transactions (90d)
1
Beneficial owners (>5%)
28
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Montrago Trustees Limited | 14.44M | 39.30% | — | 14.44M | — | 10.00 | OO | Republic of Cyprus | 2021-06-30 | ↗ |
| 2 | Skorpios Trust | 14.44M | 39.30% | — | 14.44M | — | 11.00 | OO | — | 2021-06-30 | ↗ |
| 3 | Ezbon International Limited | 7.54M | 20.50% | — | 7.54M | — | 10.00 | CO | British Virgin Islands | 2021-06-30 | ↗ |
| 4 | Blue Horizon Enterprise Ltd. | 6.91M | 18.80% | — | 6.91M | — | 11.00 | CO | — | 2021-06-30 | ↗ |
| 5 | Baker Bros. Advisors (GP) LLC | 4.37M | 8.30% | 4.37M | — | 4.37M | — | HC, OO | Delaware | 2024-11-14 | ↗ |
| 6 | Baker Bros. Advisors LP | 4.37M | 8.30% | 4.37M | — | 4.37M | — | IA, PN | Delaware | 2024-11-14 | ↗ |
| 7 | Felix J. Baker | 4.37M | 8.30% | 4.37M | — | 4.37M | — | HC, IN | Delaware | 2024-11-14 | ↗ |
| 8 | Julian C. Baker | 4.37M | 8.30% | 4.37M | — | 4.37M | — | HC, IN | Delaware | 2024-11-14 | ↗ |
| 9 | Abigail P. Johnson | 3.60M | 9.94% | — | — | 3.60M | — | IN | United States of America | 2021-02-08 | ↗ |
| 10 | FMR LLC | 3.60M | 9.94% | 696.6K | — | 3.60M | — | HC | Delaware | 2021-02-08 | ↗ |
| 11 | Jeremy C. Green | 2.69M | 7.40% | — | 2.69M | — | — | HC, IN | Delaware | 2021-02-16 | ↗ |
| 12 | Redmile Group, LLC | 2.69M | 7.40% | — | 2.69M | — | — | IA, OO | Delaware | 2021-02-16 | ↗ |
| 13 | Lynx1 Capital Management LP | 2.66M | 6.00% | — | 2.66M | — | — | PN | Delaware | 2023-11-06 | ↗ |
| 14 | Weston Nichols | 2.66M | 6.00% | — | 2.66M | — | — | IN | Delaware | 2023-11-06 | ↗ |
| 15 | Morgan Stanley | 2.45M | 6.20% | — | — | — | 13.00 | HC, CO | Delaware. | 2023-02-10 | ↗ |
| 16 | Morgan Stanley Capital Services LLC | 2.43M | 6.20% | — | — | — | 13.00 | BD, CO | Delaware. | 2023-02-10 | ↗ |
| 17 | 27-0423711 | 2.28M | 5.77% | 2.28M | — | 2.28M | — | — | Delaware | 2024-02-26 | ↗ |
| 18 | The Vanguard Group - 23-1945930 | 1.91M | 5.20% | — | — | — | 47.5K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 19 | LLC | 1.83M | 5.58% | — | — | — | 1.83M | BD | New York | 2020-02-14 | ↗ |
| 20 | Gilder, Gagnon, Howe & Co. LLC | 1.47M | 4.06% | — | — | — | — | BD | New York | 2021-02-16 | ↗ |
| 21 | Bihua Chen | 1.44M | 3.97% | — | 1.44M | — | — | IN | United States | 2021-02-16 | ↗ |
| 22 | Cormorant Asset Management, LP | 1.44M | 3.97% | — | 1.44M | — | — | PN | Delaware | 2021-02-16 | ↗ |
| 23 | Cormorant Private Healthcare Fund II, LP | 538.8K | 1.49% | — | 538.8K | — | — | PN | Delaware | 2021-02-16 | ↗ |
| 24 | Cormorant Private Healthcare GP II, LLC | 538.8K | 1.49% | — | 538.8K | — | — | OO | Delaware | 2021-02-16 | ↗ |
| 25 | Cormorant Private Healthcare Fund I, LP | 449.0K | 1.24% | — | 449.0K | — | — | PN | Delaware | 2021-02-16 | ↗ |
| 26 | Cormorant Private Healthcare GP, LLC | 449.0K | 1.24% | — | 449.0K | — | — | OO | Delaware | 2021-02-16 | ↗ |
| 27 | Cormorant Global Healthcare GP, LLC | 434.5K | 1.20% | — | 434.5K | — | — | OO | Delaware | 2021-02-16 | ↗ |
| 28 | Cormorant Global Healthcare Master Fund, LP | 434.5K | 1.20% | — | 434.5K | — | — | PN | Cayman Islands | 2021-02-16 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
35
-156 vs prev Q
New positions
8
Closed positions
157
Increased
22
Reduced
4
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 16.6K +16.6K (+100.0%) | 527.55M +527.6M (+100.0%) | 0.03% +0.028 pp | 0.46% +0.461 pp | USD31.74 +0.0% | 1 qtrs NEW |
| 2 | FMR LLC | 5.60M -1.3M (-18.4%) | 177.77M +16.4M (+10.2%) | 9.56% -2.209 pp | 0.01% +0.001 pp | USD9.89 +220.9% | 27 qtrs — |
| 3 | RTW INVESTMENTS, LP | 5.55M +423.3K (+8.3%) | 176.06M +55.7M (+46.2%) | 9.46% +0.684 pp | 1.76% +0.280 pp | USD12.78 +148.4% | 27 qtrs — |
| 4 | LYNX1 CAPITAL MANAGEMENT LP | 5.40M +— (+0.0%) | 171.54M +61.7M (+56.1%) | 9.22% -0.041 pp | 34.73% +12.360 pp | USD8.50 +273.4% | 10 qtrs — |
| 5 | BLACKROCK, INC. | 5.21M -774.9K (-12.9%) | 165.45M +24.7M (+17.6%) | 8.89% -1.367 pp | 0.00% +0.000 pp | USD12.33 +157.4% | 6 qtrs — |
| 6 | REDMILE GROUP, LLC | 4.03M -141.5K (-3.4%) | 128.04M +29.9M (+30.5%) | 6.88% -0.273 pp | 9.43% -0.118 pp | USD11.49 +176.2% | 27 qtrs — |
| 7 | MORGAN STANLEY | 3.55M +9.1K (+0.3%) | 112.56M +29.4M (+35.4%) | 6.05% -0.011 pp | 0.01% +0.002 pp | USD15.79 +101.0% | 27 qtrs — |
| 8 | BAKER BROS. ADVISORS LP | 3.34M -1.3M (-28.0%) | 105.91M -3.0M (-2.7%) | 5.69% -2.248 pp | 0.62% -0.167 pp | USD11.11 +185.7% | 14 qtrs — |
| 9 | TORONTO DOMINION BANK | 3.17M +— (+0.0%) | 100.72M +26.1M (+35.1%) | 5.41% -0.024 pp | 0.15% +0.033 pp | USD11.03 +187.8% | 5 qtrs — |
| 10 | VANGUARD GROUP INC | 3.15M -14.6K (-0.5%) | 99.96M +25.6M (+34.4%) | 5.37% -0.049 pp | 0.00% +0.000 pp | USD19.21 +65.2% | 27 qtrs — |
| 11 | STATE STREET CORP | 2.50M +1.1M (+75.2%) | 79.29M +45.8M (+136.6%) | 4.26% +1.819 pp | 0.00% +0.002 pp | USD23.79 +33.4% | 26 qtrs — |
| 12 | BVF INC/IL | 2.27M +608.6K (+36.7%) | 71.91M +33.0M (+84.7%) | 3.87% +1.026 pp | 2.42% +0.842 pp | USD25.71 +23.5% | 2 qtrs — |
| 13 | SIREN, L.L.C. | 2.25M +— (+0.0%) | 71.33M +18.5M (+35.1%) | 3.83% -0.017 pp | 2.13% +0.062 pp | USD10.55 +200.9% | 5 qtrs — |
| 14 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1.82M +1.8M (+100.0%) | 57.88M +57.9M (+100.0%) | 3.11% +3.111 pp | 0.74% +0.739 pp | USD31.74 +0.0% | 1 qtrs NEW |
| 15 | JANUS HENDERSON GROUP PLC | 1.45M +1.1M (+333.8%) | 46.03M +38.2M (+485.6%) | 2.48% +1.902 pp | 0.02% +0.017 pp | USD29.72 +6.8% | 7 qtrs — |
| 16 | POLAR CAPITAL HOLDINGS PLC | 1.27M -54.3K (-4.1%) | 40.28M +9.2M (+29.5%) | 2.17% -0.103 pp | 0.16% +0.006 pp | USD15.39 +106.2% | 3 qtrs — |
| 17 | ASSENAGON ASSET MANAGEMENT S.A. | 1.23M +327.5K (+36.4%) | 38.97M +17.8M (+84.2%) | 2.09% +0.552 pp | 0.05% +0.025 pp | USD21.44 +48.0% | 7 qtrs — |
| 18 | POINT72 ASSET MANAGEMENT, L.P. | 1.22M -84.5K (-6.5%) | 38.79M +8.1M (+26.3%) | 2.09% -0.154 pp | 0.04% -0.008 pp | USD23.50 +35.1% | 2 qtrs — |
| 19 | GEODE CAPITAL MANAGEMENT, LLC | 1.17M +19.1K (+1.7%) | 37.02M +10.1M (+37.3%) | 1.99% +0.024 pp | 0.00% +0.001 pp | USD21.24 +49.4% | 26 qtrs — |
| 20 | GOLDMAN SACHS GROUP INC | 1.14M -8.2K (-0.7%) | 36.27M +9.2M (+34.1%) | 1.95% -0.023 pp | 0.00% +0.001 pp | USD7.32 +333.6% | 27 qtrs — |
| 21 | DIMENSIONAL FUND ADVISORS LP | 827.1K +148.8K (+21.9%) | 26.25M +10.3M (+64.6%) | 1.41% +0.249 pp | 0.01% +0.002 pp | USD16.03 +98.0% | 22 qtrs — |
| 22 | BIOIMPACT CAPITAL LLC | 770.3K -19.4K (-2.5%) | 24.45M +5.9M (+31.7%) | 1.31% -0.039 pp | 2.80% -0.240 pp | USD11.79 +169.2% | 6 qtrs — |
| 23 | WELLINGTON MANAGEMENT GROUP LLP | 735.8K -2.0K (-0.3%) | 23.35M +6.0M (+34.7%) | 1.26% -0.009 pp | 0.00% +0.001 pp | USD21.63 +46.7% | 16 qtrs — |
| 24 | OPALEYE MANAGEMENT INC. | 695.0K +13.0K (+1.9%) | 22.06M +6.0M (+37.6%) | 1.19% +0.017 pp | 2.91% +0.644 pp | USD11.96 +165.4% | 5 qtrs — |
| 25 | CAPTION MANAGEMENT, LLC | 502.1K +2.1K (+0.4%) | 15.94M +4.2M (+35.6%) | 0.86% 0.000 pp | 0.11% +0.018 pp | USD23.53 +34.9% | 2 qtrs — |
| 26 | TANG CAPITAL MANAGEMENT LLC | 500.0K +— (+0.0%) | 15.87M +4.1M (+35.1%) | 0.85% -0.004 pp | 0.78% +0.332 pp | USD9.28 +242.0% | 5 qtrs — |
| 27 | CANDRIAM S.C.A. | 446.7K +446.7K (+100.0%) | 14.18M +14.2M (+100.0%) | 0.76% +0.762 pp | 0.07% +0.071 pp | USD31.74 +0.0% | 1 qtrs NEW |
| 28 | PARKMAN HEALTHCARE PARTNERS LLC | 430.2K +180.2K (+72.1%) | 13.65M +7.8M (+132.4%) | 0.73% +0.306 pp | 1.30% +0.687 pp | USD26.95 +17.8% | 2 qtrs — |
| 29 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 410.9K +8.0K (+2.0%) | 13.04M +3.6M (+37.7%) | 0.70% +0.011 pp | 0.00% +0.001 pp | USD20.25 +56.7% | 26 qtrs — |
| 30 | NORTHERN TRUST CORP | 403.2K -11.7K (-2.8%) | 12.80M +3.0M (+31.2%) | 0.69% -0.023 pp | 0.00% +0.000 pp | USD16.73 +89.7% | 26 qtrs — |
| 31 | ERSTE ASSET MANAGEMENT GMBH | 396.0K +— (+0.0%) | 12.60M +2.8M (+28.6%) | 0.68% -0.003 pp | 0.11% +0.011 pp | USD6.65 +377.3% | 4 qtrs — |
| 32 | PRICE T ROWE ASSOCIATES INC /MD/ | 372.3K +321.1K (+626.3%) | 11.82M +10.6M (+880.7%) | 0.64% +0.547 pp | 0.00% +0.001 pp | USD31.53 +0.7% | 27 qtrs — |
| 33 | JPMORGAN CHASE & CO | 277.9K +253.6K (+1,040.2%) | 8.82M +8.2M (+1,440.0%) | 0.47% +0.432 pp | 0.00% +0.001 pp | USD29.98 +5.9% | 26 qtrs — |
| 34 | BIRCHVIEW CAPITAL, LP | 260.0K +50.0K (+23.8%) | 8.25M +3.3M (+67.2%) | 0.44% +0.084 pp | 4.83% +1.106 pp | USD12.03 +163.8% | 24 qtrs — |
| 35 | INVESCO LTD. | 259.5K +51.5K (+24.7%) | 8.24M +3.3M (+68.5%) | 0.44% +0.086 pp | 0.00% +0.001 pp | USD22.98 +38.1% | 7 qtrs — |
| 36 | BAILLIE GIFFORD & CO | 246.9K +246.9K (+100.0%) | 7.84M +7.8M (+100.0%) | 0.42% +0.421 pp | 0.01% +0.007 pp | USD31.74 +0.0% | 1 qtrs NEW |
| 37 | RHENMAN & PARTNERS ASSET MANAGEMENT AB | 216.0K -34.0K (-13.6%) | 6.86M +980.8K (+16.7%) | 0.37% -0.060 pp | 0.64% -0.009 pp | USD23.50 +35.1% | 2 qtrs — |
| 38 | BANK OF AMERICA CORP /DE/ | 206.2K -43.3K (-17.4%) | 6.54M +681.5K (+11.6%) | 0.35% -0.076 pp | 0.00% +0.000 pp | USD6.87 +362.0% | 26 qtrs — |
| 39 | GRANAHAN INVESTMENT MANAGEMENT, LLC | 191.4K -62.5K (-24.6%) | 6.07M +108.3K (+1.8%) | 0.33% -0.109 pp | 0.26% +0.016 pp | USD8.25 +284.7% | 15 qtrs — |
| 40 | UBS GROUP AG | 169.7K -136.3K (-44.5%) | 5.39M -1.8M (-25.1%) | 0.29% -0.235 pp | 0.00% 0.000 pp | USD11.52 +175.5% | 20 qtrs — |
| 41 | FIRST TRUST ADVISORS LP | 162.7K +10.4K (+6.8%) | 5.16M +1.6M (+44.3%) | 0.28% +0.017 pp | 0.00% +0.001 pp | USD24.03 +32.1% | 2 qtrs — |
| 42 | BARCLAYS PLC | 150.9K +71.2K (+89.3%) | 4.79M +3.8M (+388.9%) | 0.26% +0.121 pp | 0.00% +0.001 pp | USD20.93 +51.6% | 27 qtrs — |
| 43 | BANK OF NEW YORK MELLON CORP | 140.8K +20.4K (+16.9%) | 4.47M +1.6M (+57.9%) | 0.24% +0.034 pp | 0.00% +0.000 pp | USD20.38 +55.7% | 26 qtrs — |
| 44 | FRANKLIN RESOURCES INC | 132.2K +16.4K (+14.1%) | 4.20M +1.5M (+54.2%) | 0.23% +0.027 pp | 0.00% +0.000 pp | USD17.41 +82.3% | 8 qtrs — |
| 45 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 126.4K +— (+0.0%) | 4.01M +1.0M (+35.1%) | 0.22% -0.001 pp | 0.06% +0.015 pp | USD10.80 +193.9% | 4 qtrs — |
| 46 | GILDER GAGNON HOWE & CO LLC | 122.4K -32.7K (-21.1%) | 3.89M +240.1K (+6.6%) | 0.21% -0.057 pp | 0.04% +0.004 pp | USD12.13 +161.7% | 27 qtrs — |
| 47 | EAM INVESTORS, LLC | 117.8K -2.4K (-2.0%) | 3.74M +961.1K (+34.6%) | 0.20% -0.005 pp | 0.42% +0.098 pp | USD23.50 +35.1% | 2 qtrs — |
| 48 | HIGHVISTA STRATEGIES LLC | 115.5K +115.5K (+100.0%) | 3.67M +3.7M (+100.0%) | 0.20% +0.197 pp | 0.94% +0.944 pp | USD31.74 +0.0% | 1 qtrs NEW |
| 49 | AMERICAN CENTURY COMPANIES INC | 115.1K +16.0K (+16.2%) | 3.65M +1.3M (+56.9%) | 0.20% +0.027 pp | 0.00% +0.001 pp | USD21.76 +45.9% | 3 qtrs — |
| 50 | DAFNA CAPITAL MANAGEMENT LLC | 108.9K -60.9K (-35.9%) | 3.46M -534.4K (-13.4%) | 0.19% -0.105 pp | 0.80% -0.183 pp | USD9.56 +232.0% | 8 qtrs — |
| 51 | NUVEEN, LLC | 104.3K -1.7K (-1.6%) | 3.31M +818.4K (+32.9%) | 0.18% -0.004 pp | 0.00% +0.000 pp | USD7.21 +340.2% | 4 qtrs — |
| 52 | RAFFERTY ASSET MANAGEMENT, LLC | 90.2K +54.9K (+155.3%) | 2.86M +2.0M (+244.8%) | 0.15% +0.093 pp | 0.01% +0.007 pp | USD24.72 +28.4% | 7 qtrs — |
| 53 | PENSERRA CAPITAL MANAGEMENT LLC | 88.5K -62.1K (-41.2%) | 2.81M -730.0K (-20.6%) | 0.15% -0.107 pp | 0.03% -0.009 pp | USD23.50 +35.1% | 2 qtrs — |
| 54 | QUANTEDGE CAPITAL PTE LTD | 87.2K +47.2K (+118.0%) | 2.77M +1.8M (+194.4%) | 0.15% +0.080 pp | 1.32% +0.805 pp | USD27.96 +13.5% | 2 qtrs — |
| 55 | SWISS NATIONAL BANK | 75.7K +1.6K (+2.2%) | 2.40M +661.4K (+38.0%) | 0.13% +0.002 pp | 0.00% +0.000 pp | USD15.39 +106.2% | 7 qtrs — |
| 56 | ALYESKA INVESTMENT GROUP, L.P. | 75.0K +75.0K (+100.0%) | 2.38M +2.4M (+100.0%) | 0.13% +0.128 pp | 0.01% +0.007 pp | USD31.74 +0.0% | 1 qtrs NEW |
| 57 | PALO ALTO INVESTORS LP | 72.0K -33.4K (-31.7%) | 2.29M -191.6K (-7.7%) | 0.12% -0.058 pp | 0.32% -0.140 pp | USD13.49 +135.3% | 8 qtrs — |
| 58 | PRINCIPAL FINANCIAL GROUP INC | 70.3K +25.1K (+55.5%) | 2.23M +1.2M (+110.0%) | 0.12% +0.042 pp | 0.00% +0.001 pp | USD26.44 +20.0% | 2 qtrs — |
| 59 | JANE STREET GROUP, LLC | 67.1K +67.1K (+100.0%) | 2.13M +2.1M (+100.0%) | 0.11% +0.115 pp | 0.00% +0.000 pp | USD31.74 +0.0% | 9 qtrs — |
| 60 | ALPS ADVISORS INC | 66.5K +21.8K (+48.9%) | 2.11M +1.1M (+101.1%) | 0.11% +0.037 pp | 0.01% +0.006 pp | USD20.69 +53.4% | 5 qtrs — |
| 61 | SCHONFELD STRATEGIC ADVISORS LLC | 63.1K -174.9K (-73.5%) | 2.00M -3.6M (-64.2%) | 0.11% -0.300 pp | 0.01% -0.023 pp | USD13.93 +127.9% | 5 qtrs — |
| 62 | HUSSMAN STRATEGIC ADVISORS, INC. | 63.0K +63.0K (+100.0%) | 2.00M +2.0M (+100.0%) | 0.11% +0.108 pp | 0.48% +0.483 pp | USD31.74 +0.0% | 1 qtrs NEW |
| 63 | RHUMBLINE ADVISERS | 62.4K -5.9K (-8.6%) | 1.98M +375.9K (+23.4%) | 0.11% -0.011 pp | 0.00% +0.000 pp | USD16.43 +93.2% | 25 qtrs — |
| 64 | UBS ASSET MANAGEMENT AMERICAS INC | 57.2K -18.6K (-24.6%) | 1.82M +33.2K (+1.9%) | 0.10% -0.032 pp | 0.00% +0.000 pp | USD12.08 +162.7% | 7 qtrs — |
| 65 | PRIVIUM FUND MANAGEMENT B.V. | 55.0K +55.0K (+100.0%) | 1.75M +1.7M (+100.0%) | 0.09% +0.094 pp | 0.32% +0.321 pp | USD31.74 +0.0% | 1 qtrs NEW |
| 66 | WOODLINE PARTNERS LP | 50.1K -45.0K (-47.3%) | 1.59M -644.5K (-28.8%) | 0.09% -0.078 pp | 0.01% -0.004 pp | USD10.74 +195.5% | 12 qtrs — |
| 67 | D. E. SHAW & CO., INC. | 49.9K -2.7K (-5.2%) | 1.58M +347.5K (+28.1%) | 0.09% -0.005 pp | 0.00% +0.000 pp | USD16.41 +93.4% | 14 qtrs — |
| 68 | WELLS FARGO & COMPANY/MN | 49.6K +21.5K (+76.6%) | 1.57M +914.2K (+138.6%) | 0.08% +0.037 pp | 0.00% +0.000 pp | USD21.06 +50.7% | 26 qtrs — |
| 69 | NOMURA HOLDINGS INC | 44.4K -36.9K (-45.4%) | 1.41M -500.7K (-26.2%) | 0.08% -0.064 pp | 0.00% -0.001 pp | USD23.50 +35.1% | 2 qtrs — |
| 70 | CREATIVE PLANNING | 41.7K -1.6K (-3.7%) | 1.32M +306.3K (+30.1%) | 0.07% -0.003 pp | 0.00% +0.000 pp | USD10.01 +217.1% | 4 qtrs — |
| 71 | VICTORY CAPITAL MANAGEMENT INC | 41.1K +41.1K (+100.0%) | 1.31M +1.3M (+100.0%) | 0.07% +0.070 pp | 0.00% +0.001 pp | USD31.74 +0.0% | 1 qtrs NEW |
| 72 | PLATINUM INVESTMENT MANAGEMENT LTD | 40.8K +7.9K (+24.1%) | 1.30M +522.3K (+67.6%) | 0.07% +0.013 pp | 0.30% +0.249 pp | USD25.10 +26.5% | 2 qtrs — |
| 73 | ALLIANCEBERNSTEIN L.P. | 40.6K +— (+0.0%) | 1.29M +334.8K (+35.1%) | 0.07% 0.000 pp | 0.00% +0.000 pp | USD17.11 +85.5% | 24 qtrs — |
| 74 | KENNONDALE CAPITAL MANAGEMENT LLC | 38.7K -31.0K (-44.5%) | 1.23M -409.4K (-25.0%) | 0.07% -0.053 pp | 0.90% -0.350 pp | USD10.00 +217.4% | 4 qtrs — |
| 75 | HARVEST INVESTMENT SERVICES, LLC | 38.3K +38.3K (+100.0%) | 1.22M +1.2M (+100.0%) | 0.07% +0.065 pp | 0.23% +0.230 pp | USD31.74 +0.0% | 1 qtrs NEW |
| 76 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 37.1K +5.1K (+15.8%) | 1.18M +424.8K (+56.4%) | 0.06% +0.008 pp | 0.00% +0.000 pp | USD16.46 +92.8% | 26 qtrs — |
| 77 | LEGAL & GENERAL GROUP PLC | 36.4K -1.4K (-3.8%) | 1.15M +266.4K (+30.0%) | 0.06% -0.003 pp | 0.00% +0.000 pp | USD15.42 +105.8% | 26 qtrs — |
| 78 | CANADA PENSION PLAN INVESTMENT BOARD | 35.2K +35.2K (+100.0%) | 1.12M +1.1M (+100.0%) | 0.06% +0.060 pp | 0.00% +0.001 pp | USD31.74 +0.0% | 1 qtrs NEW |
| 79 | DEUTSCHE BANK AG\ | 33.4K +9.2K (+37.9%) | 1.06M +490.9K (+86.2%) | 0.06% +0.016 pp | 0.00% +0.000 pp | USD18.81 +68.7% | 26 qtrs — |
| 80 | PROFUND ADVISORS LLC | 33.4K +33.4K (+100.0%) | 1.06M +1.1M (+100.0%) | 0.06% +0.057 pp | 0.03% +0.032 pp | USD31.74 +0.0% | 7 qtrs — |
| 81 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 32.5K -17.9K (-35.6%) | 1.03M -155.7K (-13.1%) | 0.06% -0.031 pp | 0.00% 0.000 pp | USD12.17 +160.8% | 7 qtrs — |
| 82 | AQR CAPITAL MANAGEMENT LLC | 29.5K +354.0 (+1.2%) | 935.3K +251.1K (+36.7%) | 0.05% +0.000 pp | 0.00% +0.000 pp | USD11.81 +168.8% | 6 qtrs — |
| 83 | READYSTATE ASSET MANAGEMENT LP | 29.1K +29.1K (+100.0%) | 922.3K +922.3K (+100.0%) | 0.05% +0.050 pp | 0.04% +0.037 pp | USD31.74 +0.0% | 1 qtrs NEW |
| 84 | J. GOLDMAN & CO LP | 27.0K -6.8K (-20.1%) | 857.0K +62.7K (+7.9%) | 0.05% -0.012 pp | 0.02% +0.003 pp | USD23.50 +35.1% | 2 qtrs — |
| 85 | CRESSET ASSET MANAGEMENT, LLC | 26.3K -411.0 (-1.5%) | 835.6K +207.3K (+33.0%) | 0.04% -0.001 pp | 0.00% +0.001 pp | USD23.50 +35.1% | 2 qtrs — |
| 86 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 26.2K -14.3K (-35.3%) | 831.6K -120.2K (-12.6%) | 0.04% -0.025 pp | 0.00% +0.000 pp | USD7.40 +328.9% | 8 qtrs — |
| 87 | SG AMERICAS SECURITIES, LLC | 25.8K +16.8K (+187.2%) | 820.0K +609.0K (+288.6%) | 0.04% +0.029 pp | 0.00% +0.000 pp | USD28.87 +9.9% | 2 qtrs — |
| 88 | METLIFE INVESTMENT MANAGEMENT, LLC | 25.3K +— (+0.0%) | 803.7K +208.6K (+35.1%) | 0.04% 0.000 pp | 0.00% +0.001 pp | USD16.80 +88.9% | 25 qtrs — |
| 89 | ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC | 24.5K -10.6K (-30.2%) | 755.9K -68.0K (-8.3%) | 0.04% -0.018 pp | 0.00% 0.000 pp | USD11.35 +179.6% | 3 qtrs — |
| 90 | AMERIPRISE FINANCIAL INC | 21.1K +80.0 (+0.4%) | 669.0K +175.5K (+35.6%) | 0.04% +0.000 pp | 0.00% +0.000 pp | USD23.53 +34.9% | 2 qtrs — |
| 91 | TUDOR INVESTMENT CORP ET AL | 19.3K +19.3K (+100.0%) | 612.9K +612.9K (+100.0%) | 0.03% +0.033 pp | 0.00% +0.001 pp | USD31.74 +0.0% | 1 qtrs NEW |
| 92 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 19.1K +19.1K (+100.0%) | 606.3K +606.3K (+100.0%) | 0.03% +0.033 pp | 0.00% +0.000 pp | USD31.74 +0.0% | 1 qtrs NEW |
| 93 | INTECH INVESTMENT MANAGEMENT LLC | 18.7K +5.5K (+41.9%) | 592.0K +283.1K (+91.6%) | 0.03% +0.009 pp | 0.01% +0.003 pp | USD16.84 +88.5% | 6 qtrs — |
| 94 | DIADEMA PARTNERS LP | 17.2K +17.2K (+100.0%) | 545.3K +545.3K (+100.0%) | 0.03% +0.029 pp | 0.09% +0.094 pp | USD31.74 +0.0% | 1 qtrs NEW |
| 95 | SEI INVESTMENTS CO | 16.6K +181.0 (+1.1%) | 527.9K +141.3K (+36.6%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD23.59 +34.5% | 2 qtrs — |
| 96 | AVIVA PLC | 15.9K -6.4K (-28.9%) | 503.7K -20.7K (-4.0%) | 0.03% -0.011 pp | 0.00% 0.000 pp | USD11.35 +179.6% | 3 qtrs — |
| 97 | CITADEL ADVISORS LLC | 15.9K -58.2K (-78.6%) | 503.1K -1.2M (-71.1%) | 0.03% -0.100 pp | 0.00% 0.000 pp | USD10.50 +202.3% | 6 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
1.8K
Cash buys
—
Cash sales
1.00
Net activity
-1,838
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | Ticho Barry | Officer | S-Sale | D | Common Stock | 2,243 | 32.79 | 73.5K | 36,621 | D | ↗ |
| 2026-04-03 | Kahn Clare | Director | A-Award | A | Stock Option (Right to Buy) | 30,782 | 32.79 | 1.01M | 30,782 | D | ↗ |
| 2026-04-01 | Ticho Barry | Officer | S-Sale | D | Common Stock | 1,838 | 32.66 | 60.0K | 38,864 | D | ↗ |
| 2026-03-20 | Allan Jonathan | Officer | S-Sale | D | Common Stock | 8,692 | 33.64 | 292.4K | 20,144 | D | ↗ |
| 2026-03-19 | Ticho Barry | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,365 | 2.19 | 3.0K | 83,035 | D | ↗ |
| 2026-03-18 | Ticho Barry | Officer | S-Sale | D | Common Stock | 6,100 | 31.28 | 190.8K | 41,384 | D | ↗ |
| 2026-03-18 | Leggett Thomas | Officer | S-Sale | D | Common Stock | 2,173 | 31.28 | 68.0K | 10,381 | D | ↗ |
| 2026-03-18 | Hoitt Jason | Officer | S-Sale | D | Common Stock | 30 | 32.85 | 985.50 | 10,276 | D | ↗ |
| 2026-03-18 | Allan Jonathan | Officer | S-Sale | D | Common Stock | 72 | 32.85 | 2.4K | 28,836 | D | ↗ |
| 2026-03-17 | Ticho Barry | Officer | S-Sale | D | Common Stock | 3,577 | 32.74 | 117.1K | 50,071 | D | ↗ |
| 2026-03-17 | Leggett Thomas | Officer | S-Sale | D | Common Stock | 922 | 33.38 | 30.8K | 12,554 | D | ↗ |
| 2026-03-17 | Hoitt Jason | Officer | S-Sale | D | Common Stock | 748 | 33.38 | 25.0K | 12,207 | D | ↗ |
| 2026-03-17 | Allan Jonathan | Officer | S-Sale | D | Common Stock | 2,476 | 32.74 | 81.1K | 35,255 | D | ↗ |
| 2026-03-15 | Ticho Barry | Officer | M-Exempt | D | Restricted Stock Units | 13,100 | 0.00 | — | 13,100 | D | ↗ |
| 2026-03-15 | Leggett Thomas | Officer | M-Exempt | A | Common Stock | 14,750 | 0.00 | — | 14,750 | D | ↗ |
| 2026-03-15 | Kaye Edward M. MD | Director | M-Exempt | D | Restricted Stock Units | 35,500 | 0.00 | — | 35,500 | D | ↗ |
| 2026-03-15 | Hoitt Jason | Officer | M-Exempt | D | Restricted Stock Units | 10,000 | 0.00 | — | 30,000 | D | ↗ |
| 2026-03-15 | Allan Jonathan | Officer | M-Exempt | D | Restricted Stock Units | 7,475 | 0.00 | — | 7,475 | D | ↗ |
| 2026-03-13 | LEVIN ARTHUR A | Director | S-Sale | D | Common Stock | 605 | 36.80 | 22.3K | 4,237 | D | ↗ |
| 2026-03-10 | TZIANABOS ARTHUR | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,955 | 8.33 | 32.9K | 118,696 | D | ↗ |
| 2026-03-10 | Krainer Adrian R. | Director | S-Sale | D | Common Stock | 33,243 | 39.74 | 1.32M | 283,302 | D | ↗ |
| 2026-03-02 | Krainer Adrian R. | Director | S-Sale | D | Common Stock | 7,229 | 39.66 | 286.7K | 316,545 | D | ↗ |
| 2026-02-17 | Ticho Barry | Officer | A-Award | A | Restricted Stock Units | 40,000 | 0.00 | — | 40,000 | D | ↗ |
| 2026-02-17 | SMITH IAN F | Director / Officer | A-Award | A | Restricted Stock Units | 129,000 | 0.00 | — | 129,000 | D | ↗ |
| 2026-02-17 | Leggett Thomas | Officer | A-Award | A | Restricted Stock Units | 40,000 | 0.00 | — | 40,000 | D | ↗ |
| 2026-02-17 | Hoitt Jason | Officer | A-Award | A | Restricted Stock Units | 48,000 | 0.00 | — | 48,000 | D | ↗ |
| 2026-02-17 | Allan Jonathan | Officer | A-Award | A | Restricted Stock Units | 35,000 | 0.00 | — | 35,000 | D | ↗ |
| 2025-12-31 | LEVIN ARTHUR A | Director | M-Exempt | A | Common Stock | 1,211 | 0.00 | — | 4,842 | D | ↗ |
| 2025-12-08 | Kaye Edward M. MD | Director | S-Sale | D | Common Stock | 3,825 | 31.44 | 120.3K | 58,729 | D | ↗ |
| 2025-12-08 | Allan Jonathan | Officer | S-Sale | D | Common Stock | 1,300 | 31.60 | 41.1K | 14,509 | D | ↗ |
| 2025-12-05 | Ticho Barry | Officer | S-Sale | D | Common Stock | 1,673 | 31.33 | 52.4K | 21,787 | D | ↗ |
| 2025-12-05 | Kaye Edward M. MD | Director | S-Sale | D | Common Stock | 500 | 31.85 | 15.9K | 62,554 | D | ↗ |
| 2025-12-05 | Allan Jonathan | Officer | S-Sale | D | Common Stock | 1,004 | 31.33 | 31.5K | 23,590 | D | ↗ |
| 2025-12-04 | Ticho Barry | Officer | S-Sale | D | Common Stock | 323 | 31.32 | 10.1K | 23,460 | D | ↗ |
| 2025-12-04 | Kaye Edward M. MD | Director | S-Sale | D | Common Stock | 1,231 | 31.32 | 38.6K | 71,102 | D | ↗ |
| 2025-12-04 | Allan Jonathan | Officer | S-Sale | D | Common Stock | 824 | 30.76 | 25.3K | 24,788 | D | ↗ |
| 2025-12-03 | Ticho Barry | Officer | S-Sale | D | Common Stock | 1,225 | 30.85 | 37.8K | 15,156 | D | ↗ |
| 2025-12-03 | Kaye Edward M. MD | Director | S-Sale | D | Common Stock | 419 | 30.34 | 12.7K | 51,956 | D | ↗ |
| 2025-12-03 | Allan Jonathan | Officer | M-Exempt | D | Performance Stock Units | 6,000 | 0.00 | — | 0 | D | ↗ |
| 2025-12-02 | Ticho Barry | Officer | S-Sale | D | Common Stock | 762 | 30.14 | 23.0K | 17,170 | D | ↗ |
| 2025-12-02 | Kaye Edward M. MD | Director | S-Sale | D | Common Stock | 661 | 29.56 | 19.5K | 52,780 | D | ↗ |
| 2025-12-02 | Allan Jonathan | Officer | S-Sale | D | Common Stock | 868 | 30.14 | 26.2K | 21,904 | D | ↗ |
| 2025-12-01 | Ticho Barry | Officer | M-Exempt | D | Restricted Stock Units | 11,981 | 0.00 | — | 0 | D | ↗ |
| 2025-12-01 | Kaye Edward M. MD | Director | M-Exempt | D | Restricted Stock Units | 4,317 | 0.00 | — | 0 | D | ↗ |
| 2025-12-01 | Allan Jonathan | Officer | M-Exempt | D | Restricted Stock Units | 12,357 | 0.00 | — | 0 | D | ↗ |
| 2025-11-24 | Krainer Adrian R. | Director | S-Sale | D | Common Stock | 40,472 | 29.72 | 1.20M | 323,774 | D | ↗ |
| 2025-11-14 | Krainer Adrian R. | Director | S-Sale | D | Common Stock | 19,790 | 26.61 | 526.7K | 384,928 | D | ↗ |
| 2025-11-03 | Ticho Barry | Officer | S-Sale | D | Common Stock | 1,455 | 26.02 | 37.9K | 7,895 | D | ↗ |
| 2025-10-08 | SMITH IAN F | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 570,000 | 30.50 | 17.39M | 570,000 | D | ↗ |
| 2025-10-08 | Kaye Edward M. MD | Director | M-Exempt | D | Stock Option (Right to Buy) | 25,000 | 0.60 | 15.0K | 542,801 | D | ↗ |
| 2025-10-03 | Kaye Edward M. MD | Director | S-Sale | D | Common Stock | 42,461 | 25.09 | 1.07M | 49,124 | D | ↗ |
| 2025-10-03 | Allan Jonathan | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 9.15 | 91.5K | 34,800 | D | ↗ |
| 2025-10-01 | Ticho Barry | Officer | S-Sale | D | Common Stock | 5,343 | 23.64 | 126.3K | 13,126 | D | ↗ |
| 2025-09-30 | LEVIN ARTHUR A | Director | M-Exempt | A | Common Stock | 1,211 | 0.00 | — | 3,631 | D | ↗ |
| 2025-09-04 | Kaye Edward M. MD | Director | D-Return | D | Employee Stock Option (Right to Buy) | 178,500 | 8.33 | 1.49M | 37,500 | D | ↗ |
| 2025-09-03 | Kaye Edward M. MD | Director | S-Sale | D | Common Stock | 45,996 | 20.13 | 925.9K | 91,585 | D | ↗ |
| 2025-09-03 | Allan Jonathan | Officer | S-Sale | D | Common Stock | 6,345 | 20.07 | 127.3K | 11,831 | D | ↗ |
| 2025-09-02 | Ticho Barry | Officer | S-Sale | D | Common Stock | 5,501 | 19.87 | 109.3K | 18,469 | D | ↗ |
| 2025-09-02 | Kaye Edward M. MD | Director | S-Sale | D | Common Stock | 14,860 | 20.14 | 299.3K | 137,581 | D | ↗ |
| 2025-09-02 | Allan Jonathan | Officer | M-Exempt | A | Common Stock | 9,150 | 7.07 | 64.7K | 33,098 | D | ↗ |
| 2025-08-29 | Kaye Edward M. MD | Director | S-Sale | D | Common Stock | 1,029 | 20.00 | 20.6K | 152,441 | D | ↗ |
| 2025-08-29 | Allan Jonathan | Officer | M-Exempt | A | Common Stock | 850 | 7.07 | 6.0K | 24,798 | D | ↗ |
| 2025-08-18 | Ticho Barry | Officer | S-Sale | D | Common Stock | 2,805 | 18.24 | 51.2K | 23,970 | D | ↗ |
| 2025-08-18 | Kaye Edward M. MD | Director | S-Sale | D | Common Stock | 12,126 | 18.24 | 221.2K | 153,470 | D | ↗ |
| 2025-08-18 | Allan Jonathan | Officer | S-Sale | D | Common Stock | 1,683 | 18.24 | 30.7K | 23,948 | D | ↗ |
| 2025-08-14 | Ticho Barry | Officer | M-Exempt | D | Performance Stock Units | 10,000 | 0.00 | — | 10,000 | D | ↗ |
| 2025-08-14 | Kaye Edward M. MD | Director | A-Award | A | Performance Stock Units | 52,500 | 0.00 | — | 52,500 | D | ↗ |
| 2025-08-14 | Allan Jonathan | Officer | M-Exempt | A | Common Stock | 6,000 | 0.00 | — | 25,631 | D | ↗ |
| 2025-08-13 | Allan Jonathan | Officer | S-Sale | D | Common Stock | 13,712 | 15.00 | 205.7K | 19,631 | D | ↗ |
| 2025-08-01 | Ticho Barry | Officer | S-Sale | D | Common Stock | 4,504 | 12.82 | 57.7K | 16,775 | D | ↗ |
| 2025-07-01 | Ticho Barry | Officer | S-Sale | D | Common Stock | 4,503 | 11.63 | 52.4K | 21,279 | D | ↗ |
| 2025-06-30 | LEVIN ARTHUR A | Director | M-Exempt | D | Restricted Stock Units | 1,210 | 0.00 | — | 2,422 | D | ↗ |
| 2025-06-18 | Hoitt Jason | Officer | — | — | Employee Stock Option (Right to Buy) | 60,000 | 8.33 | 499.8K | 0 | D | ↗ |
| 2025-06-04 | Skorpios Trust | 10% Owner | S-Sale | D | Common Stock | 3,000,000 | 10.20 | 30.60M | 3,906,181 | I | ↗ |
| 2025-06-03 | Ticho Barry | Officer | S-Sale | D | Common Stock | 6,471 | 10.03 | 64.9K | 25,782 | D | ↗ |
| 2025-06-03 | Smith Julie | Director | A-Award | A | Director Stock Option (Right to Buy) | 29,747 | 10.90 | 324.2K | 29,747 | D | ↗ |
| 2025-06-03 | Menzel Garry E | Director | A-Award | A | Director Stock Option (Right to Buy) | 29,747 | 10.90 | 324.2K | 29,747 | D | ↗ |
| 2025-06-03 | LEVIN ARTHUR A | Director | A-Award | A | Director Stock Option (Right to Buy) | 29,747 | 10.90 | 324.2K | 29,747 | D | ↗ |
| 2025-06-03 | Krainer Adrian R. | Director | A-Award | A | Director Stock Option (Right to Buy) | 29,747 | 10.90 | 324.2K | 29,747 | D | ↗ |
| 2025-06-03 | Harrison Seth Loring | Director | A-Award | A | Director Stock Option (Right to Buy) | 29,747 | 10.90 | 324.2K | 29,747 | D | ↗ |
| 2025-06-03 | Burstein Jennifer | Director | A-Award | A | Director Stock Option (Right to Buy) | 29,747 | 10.90 | 324.2K | 29,747 | D | ↗ |
| 2025-06-02 | Ticho Barry | Officer | S-Sale | D | Common Stock | 1,745 | 10.00 | 17.5K | 32,253 | D | ↗ |
| 2025-05-02 | Ticho Barry | Officer | S-Sale | D | Common Stock | 22,790 | 10.03 | 228.5K | 33,998 | D | ↗ |
| 2025-05-01 | Ticho Barry | Officer | S-Sale | D | Common Stock | 3,841 | 10.00 | 38.4K | 56,788 | D | ↗ |
| 2025-03-31 | LEVIN ARTHUR A | Director | M-Exempt | A | Common Stock | 1,210 | 0.00 | — | 1,210 | D | ↗ |
| 2025-03-20 | Ticho Barry | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 64,000 | 8.33 | 533.1K | 64,000 | D | ↗ |
| 2025-03-20 | TZIANABOS ARTHUR | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 122,651 | 8.33 | 1.02M | 122,651 | D | ↗ |
| 2025-03-20 | SMITH IAN F | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 238,420 | 8.33 | 1.99M | 238,420 | D | ↗ |
| 2025-03-20 | Leggett Thomas | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 89,000 | 8.33 | 741.4K | 89,000 | D | ↗ |
| 2025-03-20 | Kaye Edward M. MD | Director | A-Award | A | Employee Stock Option (Right to Buy) | 216,000 | 8.33 | 1.80M | 216,000 | D | ↗ |
| 2025-03-20 | Allan Jonathan | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 72,000 | 8.33 | 599.8K | 72,000 | D | ↗ |
| 2025-03-19 | Ticho Barry | Officer | S-Sale | D | Common Stock | 3,333 | 8.27 | 27.6K | 60,629 | D | ↗ |
| 2025-03-19 | LEVIN ARTHUR A | Director | A-Award | A | Restricted Stock Units | 4,842 | 0.00 | — | 4,842 | D | ↗ |
| 2025-03-19 | Kaye Edward M. MD | Director | S-Sale | D | Common Stock | 8,907 | 8.27 | 73.7K | 139,346 | D | ↗ |
| 2025-03-19 | Allan Jonathan | Officer | S-Sale | D | Common Stock | 1,945 | 8.27 | 16.1K | 31,565 | D | ↗ |
| 2025-03-18 | Ticho Barry | Officer | S-Sale | D | Common Stock | 3,884 | 8.67 | 33.7K | 63,962 | D | ↗ |
| 2025-03-18 | Kaye Edward M. MD | Director | S-Sale | D | Common Stock | 10,382 | 8.67 | 90.0K | 148,253 | D | ↗ |
| 2025-03-18 | Allan Jonathan | Officer | S-Sale | D | Common Stock | 2,266 | 8.67 | 19.6K | 33,510 | D | ↗ |
| 2025-03-15 | Ticho Barry | Officer | M-Exempt | D | Restricted Stock Units | 13,100 | 0.00 | — | 26,200 | D | ↗ |
| 2025-03-15 | Kaye Edward M. MD | Director / Officer | M-Exempt | A | Common Stock | 26,250 | 0.00 | — | 158,635 | D | ↗ |
| 2025-03-15 | Allan Jonathan | Officer | M-Exempt | A | Common Stock | 6,000 | 0.00 | — | 35,776 | D | ↗ |
| 2024-12-30 | Kaye Edward M. MD | Director / Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 35,000 | 0.60 | 21.0K | 567,801 | D | ↗ |
| 2024-12-23 | Skorpios Trust | 10% Owner | S-Sale | D | Common Stock | 2,000,000 | 11.50 | 23.00M | 6,906,181 | I | ↗ |
| 2024-12-09 | Ticho Barry | Officer | S-Sale | D | Common Stock | 2,586 | 12.99 | 33.6K | 44,746 | D | ↗ |
| 2024-12-09 | Kaye Edward M. MD | Director / Officer | S-Sale | D | Common Stock | 6,786 | 12.99 | 88.2K | 61,885 | D | ↗ |
| 2024-12-09 | Allan Jonathan | Officer | S-Sale | D | Common Stock | 12,114 | 13.69 | 165.8K | 23,028 | D | ↗ |
| 2024-12-06 | Ticho Barry | Officer | S-Sale | D | Common Stock | 13,945 | 12.78 | 178.2K | 47,332 | D | ↗ |
| 2024-12-06 | Kaye Edward M. MD | Director / Officer | S-Sale | D | Common Stock | 6,170 | 12.78 | 78.8K | 68,671 | D | ↗ |
| 2024-12-06 | Allan Jonathan | Officer | S-Sale | D | Common Stock | 9,696 | 12.78 | 123.9K | 35,142 | D | ↗ |
| 2024-12-03 | Ticho Barry | Officer | M-Exempt | A | Common Stock | 10,000 | 0.00 | — | 61,277 | D | ↗ |
| 2024-12-03 | Kaye Edward M. MD | Director / Officer | M-Exempt | A | Common Stock | 26,250 | 0.00 | — | 74,841 | D | ↗ |
| 2024-12-03 | Allan Jonathan | Officer | M-Exempt | A | Common Stock | 6,000 | 0.00 | — | 44,838 | D | ↗ |
| 2024-12-02 | Ticho Barry | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 0.60 | 6.0K | 0 | D | ↗ |
| 2024-12-01 | Ticho Barry | Officer | M-Exempt | A | Common Stock | 48,792 | 0.00 | — | 51,277 | D | ↗ |
| 2024-12-01 | Kaye Edward M. MD | Director / Officer | M-Exempt | A | Common Stock | 21,591 | 0.00 | — | 48,591 | D | ↗ |
| 2024-12-01 | Allan Jonathan | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 33,927 | 0.00 | — | 12,357 | D | ↗ |
| 2024-11-01 | Ticho Barry | Officer | M-Exempt | A | Common Stock | 10,000 | 0.60 | 6.0K | 12,485 | D | ↗ |
| 2024-10-01 | Ticho Barry | Officer | S-Sale | D | Common Stock | 10,000 | 12.06 | 120.6K | 2,485 | D | ↗ |
| 2024-09-19 | Skorpios Trust | 10% Owner | S-Sale | D | Common Stock | 1,937,500 | 14.05 | 27.22M | 8,906,181 | I | ↗ |
| 2024-09-03 | Ticho Barry | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 0.60 | 6.0K | 30,000 | — | ↗ |
| 2024-08-01 | Ticho Barry | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 0.60 | 6.0K | 40,000 | — | ↗ |
| 2024-07-02 | Nash Huw M. | Officer | S-Sale | D | Common Stock | 2,467 | 13.10 | 32.3K | 33 | — | ↗ |
| 2024-07-01 | Ticho Barry | Officer | S-Sale | D | Common Stock | 10,000 | 13.75 | 137.5K | 2,485 | — | ↗ |
| 2024-06-05 | TZIANABOS ARTHUR | Director | A-Award | A | Director Stock Option (Right to Buy) | 7,639 | 16.41 | 125.4K | 7,639 | — | ↗ |
| 2024-06-05 | Smith Julie | Director | A-Award | A | Director Stock Option (Right to Buy) | 7,639 | 16.41 | 125.4K | 7,639 | — | ↗ |
| 2024-06-05 | SMITH IAN F | Director | A-Award | A | Director Stock Option (Right to Buy) | 7,639 | 16.41 | 125.4K | 7,639 | — | ↗ |
| 2024-06-05 | Menzel Garry E | Director | A-Award | A | Director Stock Option (Right to Buy) | 7,639 | 16.41 | 125.4K | 7,639 | — | ↗ |
| 2024-06-05 | LEVIN ARTHUR A | Director | A-Award | A | Director Stock Option (Right to Buy) | 7,639 | 16.41 | 125.4K | 7,639 | — | ↗ |
| 2024-06-05 | Krainer Adrian R. | Director | A-Award | A | Director Stock Option (Right to Buy) | 7,639 | 16.41 | 125.4K | 7,639 | — | ↗ |
| 2024-06-05 | Harrison Seth Loring | Director | A-Award | A | Director Stock Option (Right to Buy) | 7,639 | 16.41 | 125.4K | 7,639 | — | ↗ |
| 2024-06-05 | Burstein Jennifer | Director | A-Award | A | Director Stock Option (Right to Buy) | 7,639 | 16.41 | 125.4K | 7,639 | — | ↗ |
| 2024-06-03 | Ticho Barry | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 0.60 | 6.0K | 60,000 | — | ↗ |
| 2024-05-20 | Nash Huw M. | Officer | S-Sale | D | Common Stock | 50,000 | 15.39 | 769.5K | 0 | — | ↗ |
| 2024-05-20 | Kaye Edward M. MD | Director / Officer | S-Sale | D | Common Stock | 39,686 | 15.39 | 610.8K | 29,664 | — | ↗ |
| 2024-05-20 | Allan Jonathan | Officer | M-Exempt | D | Stock Option (Right to Buy) | 8,599 | 7.07 | 60.8K | 25,801 | — | ↗ |
| 2024-05-15 | Leggett Thomas | Officer | A-Award | A | Stock Option (Right to Buy) | 396,200 | 14.13 | 5.60M | 396,200 | — | ↗ |
| 2024-05-07 | Leggett Thomas | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-05-01 | Ticho Barry | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 0.60 | 6.0K | 70,000 | — | ↗ |
| 2024-04-17 | Skorpios Trust | 10% Owner | S-Sale | D | Common Stock | 3,600,000 | 11.60 | 41.76M | 10,843,681 | — | ↗ |
| 2024-04-01 | Ticho Barry | Officer | M-Exempt | D | Stock Option (Right to Buy) | 442 | 0.60 | 265.20 | 80,000 | — | ↗ |
| 2024-04-01 | Nash Huw M. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 50,000 | 0.40 | 20.0K | 96,000 | — | ↗ |
| 2024-03-28 | Allan Jonathan | Officer | S-Sale | D | Common Stock | 5,026 | 13.19 | 66.3K | 2,698 | — | ↗ |
| 2024-03-27 | Tulipano Stephen J | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 60,000 | 14.17 | 850.2K | 60,000 | — | ↗ |
| 2024-03-27 | Ticho Barry | Officer | A-Award | A | Restricted Stock Units | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2024-03-27 | Nash Huw M. | Officer | A-Award | A | Restricted Stock Units | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2024-03-27 | Kaye Edward M. MD | Director / Officer | A-Award | A | Restricted Stock Units | 105,000 | 0.00 | — | 105,000 | — | ↗ |
| 2024-03-27 | Allan Jonathan | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 36,000 | 14.17 | 510.1K | 36,000 | — | ↗ |
| 2024-03-19 | Tulipano Stephen J | Officer | S-Sale | D | Common Stock | 4,116 | 6.10 | 25.1K | 20,746 | — | ↗ |
| 2024-03-19 | Ticho Barry | Officer | S-Sale | D | Common Stock | 4,116 | 6.10 | 25.1K | 11,469 | — | ↗ |
| 2024-03-19 | Nash Huw M. | Officer | S-Sale | D | Common Stock | 4,116 | 6.10 | 25.1K | 11,329 | — | ↗ |
| 2024-03-19 | Kaye Edward M. MD | Director / Officer | S-Sale | D | Common Stock | 11,150 | 6.10 | 68.0K | 69,350 | — | ↗ |
| 2024-03-19 | Allan Jonathan | Officer | S-Sale | D | Common Stock | 2,349 | 6.10 | 14.3K | 7,724 | — | ↗ |
| 2024-03-15 | Tulipano Stephen J | Officer | M-Exempt | A | Common Stock | 13,100 | 0.00 | — | 24,862 | — | ↗ |
| 2024-03-15 | Ticho Barry | Officer | M-Exempt | D | Restricted Stock Units | 13,100 | 0.00 | — | 39,300 | — | ↗ |
| 2024-03-15 | Nash Huw M. | Officer | M-Exempt | D | Restricted Stock Units | 13,100 | 0.00 | — | 39,300 | — | ↗ |
| 2024-03-15 | Kaye Edward M. MD | Director / Officer | M-Exempt | D | Restricted Stock Units | 35,500 | 0.00 | — | 106,500 | — | ↗ |
| 2024-03-15 | Allan Jonathan | Officer | M-Exempt | D | Restricted Stock Units | 7,475 | 0.00 | — | 22,425 | — | ↗ |
| 2024-03-01 | Ticho Barry | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,504 | 0.60 | 3.3K | 80,442 | — | ↗ |
| 2024-02-13 | TZIANABOS ARTHUR | Director | M-Exempt | D | Stock Option (Right to Buy) | 31,739 | 2.19 | 69.5K | 0 | — | ↗ |
| 2024-02-01 | Ticho Barry | Officer | S-Sale | D | Common Stock | 10,000 | 4.80 | 48.0K | 6,981 | — | ↗ |
| 2024-01-02 | Ticho Barry | Officer | S-Sale | D | Common Stock | 10,000 | 5.74 | 57.4K | 16,981 | — | ↗ |
| 2023-12-01 | Tulipano Stephen J | Officer | D-Return | D | Employee Stock Option (Right to Buy) | 107,400 | 20.34 | 2.18M | 0 | — | ↗ |
| 2023-12-01 | Ticho Barry | Officer | D-Return | D | Employee Stock Option (Right to Buy) | 65,600 | 60.00 | 3.94M | 0 | — | ↗ |
| 2023-12-01 | Nash Huw M. | Officer | A-Award | A | Restricted Stock Unit (RSU) | 8,463 | 0.00 | — | 8,463 | — | ↗ |
| 2023-12-01 | Kaye Edward M. MD | Director / Officer | A-Award | A | Restricted Stock Unit (RSU) | 25,908 | 0.00 | — | 25,908 | — | ↗ |
| 2023-12-01 | Allan Jonathan | Officer | A-Award | A | Restricted Stock Unit (RSU) | 46,284 | 0.00 | — | 46,284 | — | ↗ |
| 2023-09-19 | SMITH IAN F | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-07-03 | Ticho Barry | Officer | S-Sale | D | Common Stock | 15,000 | 10.60 | 159.0K | 25,895 | — | ↗ |
| 2023-06-21 | Allan Jonathan | Officer | S-Sale | D | Common Stock | 1,948 | 13.48 | 26.3K | 0 | — | ↗ |
| 2023-06-13 | TZIANABOS ARTHUR | Director | A-Award | A | Director Stock Option (Right to Buy) | 19,441 | 12.46 | 242.2K | 19,441 | — | ↗ |
| 2023-06-13 | Smith Julie | Director | A-Award | A | Director Stock Option (Right to Buy) | 19,441 | 12.46 | 242.2K | 19,441 | — | ↗ |
| 2023-06-13 | Menzel Garry E | Director | A-Award | A | Director Stock Option (Right to Buy) | 19,441 | 12.46 | 242.2K | 19,441 | — | ↗ |
| 2023-06-13 | LEVIN ARTHUR A | Director | A-Award | A | Director Stock Option (Right to Buy) | 19,441 | 12.46 | 242.2K | 19,441 | — | ↗ |
| 2023-06-13 | Krainer Adrian R. | Director | A-Award | A | Director Stock Option (Right to Buy) | 19,441 | 12.46 | 242.2K | 19,441 | — | ↗ |
| 2023-06-13 | Harrison Seth Loring | Director | A-Award | A | Director Stock Option (Right to Buy) | 19,441 | 12.46 | 242.2K | 19,441 | — | ↗ |
| 2023-06-13 | Burstein Jennifer | Director | A-Award | A | Director Stock Option (Right to Buy) | 19,441 | 12.46 | 242.2K | 19,441 | — | ↗ |
| 2023-06-01 | Ticho Barry | Officer | S-Sale | D | Common Stock | 15,000 | 11.13 | 167.0K | 40,895 | — | ↗ |
| 2023-05-04 | Ticho Barry | Officer | S-Sale | D | Common Stock | 653 | 10.00 | 6.5K | 55,895 | — | ↗ |
| 2023-05-03 | Ticho Barry | Officer | S-Sale | D | Common Stock | 24,697 | 10.14 | 250.4K | 56,548 | — | ↗ |
| 2023-05-02 | Ticho Barry | Officer | S-Sale | D | Common Stock | 5,513 | 10.00 | 55.1K | 81,245 | — | ↗ |
| 2023-05-01 | Ticho Barry | Officer | S-Sale | D | Common Stock | 24,967 | 10.00 | 249.8K | 86,758 | — | ↗ |
| 2023-03-27 | Kaye Edward M. MD | Director / Officer | M-Exempt | D | Employee Stock Option (right to buy) | 20,000 | 0.60 | 12.0K | 602,801 | — | ↗ |
| 2023-03-15 | Tulipano Stephen J | Officer | A-Award | A | Restricted Stock Unit (RSU) | 52,400 | 0.00 | — | 52,400 | — | ↗ |
| 2023-03-15 | Ticho Barry | Officer | A-Award | A | Restricted Stock Unite (RSU) | 52,400 | 0.00 | — | 52,400 | — | ↗ |
| 2023-03-15 | Nash Huw M. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 78,600 | 9.15 | 719.2K | 78,600 | — | ↗ |
| 2023-03-15 | Kaye Edward M. MD | Director / Officer | A-Award | A | Restricted Stock Unit (RSU) | 142,000 | 0.00 | — | 142,000 | — | ↗ |
| 2023-03-15 | Allan Jonathan | Officer | — | D | Employee Stock Option (Right to Buy) | 34,400 | 7.07 | 243.2K | 0 | — | ↗ |
| 2023-02-06 | Ticho Barry | Officer | S-Sale | D | Common Stock | 9,235 | 10.02 | 92.5K | 111,725 | — | ↗ |
| 2023-02-03 | Ticho Barry | Officer | S-Sale | D | Common Stock | 3,763 | 10.03 | 37.7K | 120,960 | — | ↗ |
| 2023-02-02 | Ticho Barry | Officer | S-Sale | D | Common Stock | 267 | 10.00 | 2.7K | 124,723 | — | ↗ |
| 2023-02-01 | Ticho Barry | Officer | S-Sale | D | Common Stock | 5,705 | 10.02 | 57.1K | 124,990 | — | ↗ |
| 2023-01-31 | Ticho Barry | Officer | S-Sale | D | Common Stock | 200 | 10.00 | 2.0K | 130,695 | — | ↗ |
| 2022-12-07 | Tulipano Stephen J | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 62,000 | 0.00 | — | 62,000 | — | ↗ |
| 2022-12-07 | Ticho Barry | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 62,000 | 0.00 | — | 62,000 | — | ↗ |
| 2022-12-07 | Nash Huw M. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 62,000 | 0.00 | — | 62,000 | — | ↗ |
| 2022-12-07 | Kaye Edward M. MD | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 167,050 | 0.00 | — | 167,050 | — | ↗ |
| 2022-06-07 | TZIANABOS ARTHUR | Director | A-Award | A | Director Stock Option (Right to Buy) | 21,000 | 12.96 | 272.2K | 21,000 | — | ↗ |
| 2022-06-07 | Smith Julie | Director | A-Award | A | Director Stock Option (Right to Buy) | 21,000 | 0.00 | — | 21,000 | — | ↗ |
| 2022-06-07 | Menzel Garry E | Director | A-Award | A | Director Stock Option (Right to Buy) | 21,000 | 0.00 | — | 21,000 | — | ↗ |
| 2022-06-07 | LEVIN ARTHUR A | Director | A-Award | A | Director Stock Option (Right to Buy) | 21,000 | 0.00 | — | 21,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-160.9K
Shares Outstanding
59.15M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Ian F. Smith Chief Executive Officer | 170.6K | 1.20M | 11.59M | 14.04M | — | 38.8K | 27.03M | 94.80% | ↗ |
| 2 | 2025 | Edward M. Kaye, M.D. Former Chief Executive Officer | 148.7K | — | 1.20M | 1.30M | — | 587.7K | 3.23M | 77.23% | ↗ |
| 3 | 2025 | Jason Hoitt Chief Patient Officer | 494.4K | — | 333.2K | 1.12M | 306.0K | 15.0K | 2.27M | 64.08% | ↗ |
| 4 | 2025 | Thomas Leggett Chief Financial Officer | 496.4K | — | 491.5K | 534.9K | 297.8K | 9.8K | 1.83M | 56.07% | ↗ |
| 5 | 2024 | Edward M. Kaye, M.D. Former Chief Executive Officer | 650.9K | — | 2.98M | 1.61M | 358.0K | 12.7K | 5.61M | 81.80% | ↗ |
| 6 | 2024 | Thomas Leggett Chief Financial Officer | 309.5K | — | — | 4.02M | 190.0K | — | 4.52M | 88.95% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ian F. Smith | Chief Executive Officer & Director | 1M | male |
| Jason Hoitt | Chief Patient Officer | 815.4K | male |
| Thomas Edward Leggett | Chief Financial Officer | 804.0K | male |
| Edward Kaye | Advisor & Director | 736.4K | — |
| Barry S. Ticho FACC | Chief Medical Officer | 726.5K | — |
| Adrian R. Krainer | Co-Founder & Independent Director | 45.0K | — |
| Isabel Aznarez | Co-Founder, Head of Research & Senior Vice President | — | female |
| Doug Snow | Director of Communications & Investor Relations | — | — |
| Jonathan Allan | Corporate Secretary & General Counsel | — | male |
| Sara Den Besten | Chief People Officer | — | female |
| Susan Willson | Vice President of Corporate Communications | — | — |
| Dawn Kalmar | Chief of Corporate Affairs & Strategic Partnerships | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for STOK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
